XLO XLO
Company Profile ↓Company Overview
XLO (XLO) is a publicly traded company listed on with a market capitalization of $41.27M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Net profit has compounded at 20.1% per year over the last five years.
Carries low leverage with a debt-to-equity ratio of 0.20.
Recent Developments
- Dec 2025 Revenue of $43.77M (+589.9% YoY); net profit $-35.04M.
- Trailing 12 Months Year-on-year growth — revenue +589.9%.
- 5-Year Trend Long-term compounding — profit CAGR 20.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 589.88% |
Compounded Profit Growth
| 5 Years: | 20.10% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +0.11% |
| 6 Months: | +6.67% |
| 3 Months: | +15.03% |
| 1 Month: | -1.19% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)55.31 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 20.1% over 5 years.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 2.93M | 8.08M | 19.07M | 13.69M | 12.65M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 16.78M | 22.45M | 21.00M | 25.52M | 26.76M |
| Operating Income | - | -13.85M | -14.37M | -1.93M | -11.84M | -14.11M |
| EBITDA | - | -13.35M | -13.98M | -1.59M | -11.51M | -13.77M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -13.27M | -15.84M | -16.29M | 10.36M | -9.53M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -13.27M | -15.84M | -16.29M | 10.36M | -9.53M |
| Diluted EPS | - | -2.49 | -2.24 | -1.54 | 0.81 | -0.58 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 6.34M | 43.77M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 89.15M | 79.13M | 65.99M | 85.75M |
| Operating Income | -89.15M | -79.13M | -59.65M | -41.98M |
| EBITDA | -87.30M | -77.23M | -58.00M | -40.44M |
| Interest Expense | - | - | - | - |
| Pretax Income | -88.22M | -76.40M | -58.24M | -35.04M |
| Tax Provision | - | - | - | - |
| Net Income | -88.22M | -76.40M | -58.24M | -35.04M |
| Diluted EPS | -45.08 | -38.92 | -15.26 | -4.19 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 139.16M | 60.93M | 71.08M | 154.69M |
| Current Assets | - | 124.50M | 48.13M | 60.23M | 145.03M |
| Cash & Equivalents | - | 120.39M | 44.70M | 55.29M | 137.53M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | 0 | 5.00M |
| Total Liabilities | - | 33.52M | 24.10M | 53.48M | 119.41M |
| Current Liabilities | - | 21.12M | 15.96M | 27.26M | 56.27M |
| Long Term Debt | 9.63M | 3.17M | - | - | - |
| Total Debt | - | 19.94M | 12.50M | 8.14M | 6.95M |
| Total Equity | - | 105.65M | 36.83M | 17.60M | 35.27M |
| Shares Outstanding | - | 1.96M | 1.97M | 3.27M | 4.53M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -75.72M | -68.62M | -18.38M | -4.99M |
| Investing Cash Flow | - | -1.87M | -486.00K | -36.00K | -518.00K |
| Financing Cash Flow | - | -69.00K | -6.55M | 29.20M | 87.78M |
| Capital Expenditure | - | -1.87M | -486.00K | -36.00K | -518.00K |
| Free Cash Flow | - | -77.59M | -69.11M | -18.41M | -5.51M |
| Net Change in Cash | - | -77.66M | -75.66M | 10.78M | 82.27M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | -940.2% | -95.9% |
| Net Margin % | - | - | -918.0% | -80.1% |
| ROE % | -83.5% | -207.5% | -331.0% | -99.3% |
| ROCE % | -75.5% | -176.0% | -136.1% | -42.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bain Capital Life Sciences Investors, LLC | 10.10% | 664.02K | $6.05M |
| 2 | Gilead Sciences Inc | 9.89% | 650.39K | $5.93M |
| 3 | Frazier Life Sciences Management, L.P. | 6.43% | 422.50K | $3.85M |
| 4 | Sio Capital Management, LLC | 2.32% | 152.46K | $1.39M |
| 5 | Vanguard Capital Management LLC | 1.88% | 123.66K | $1.13M |
| 6 | Caligan Partners, LP | 1.71% | 112.13K | $1.02M |
| 7 | Merck & Co., Inc. | 1.61% | 105.98K | $965.50K |
| 8 | Stonepine Capital Management, LLC | 0.98% | 64.16K | $584.51K |
| 9 | Morgan Stanley | 0.87% | 57.49K | $523.76K |
| 10 | Renaissance Technologies, LLC | 0.75% | 49.57K | $451.55K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XLO
XLO — Frequently Asked Questions
What is the current share price of XLO?
As of 2026-08-02 19:16 PDT, XLO trades at $9.11 on NASDAQ/NYSE. Its 52-week range is $7.14 to $12.08.
What is the market capitalisation of XLO?
XLO has a market capitalisation of $41.27M on NASDAQ/NYSE.
What is the P/E ratio of XLO?
XLO trades at a trailing price-to-earnings (P/E) ratio of -2.17. Its price-to-book (P/B) ratio is 1.17.
What is the return on equity (ROE) of XLO?
XLO has a return on equity (ROE) of -99.33%. Its return on capital employed (ROCE) is -42.66%.
Is XLO a good stock to buy?
This page provides a data-driven analysis of XLO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.